Literature DB >> 27372302

Influence of metabolic syndrome on upper gastrointestinal disease.

Masahiro Sogabe1,2, Toshiya Okahisa3,4, Tetsuo Kimura4, Koichi Okamoto4, Hiroshi Miyamoto4, Naoki Muguruma4, Tetsuji Takayama4.   

Abstract

A recent increase in the rate of obesity as a result of insufficient physical exercise and excess food consumption has been seen in both developed and developing countries throughout the world. Additionally, the recent increased number of obese individuals with lifestyle-related diseases associated with abnormalities in glucose metabolism, dyslipidemia, and hypertension, defined as metabolic syndrome (MS), has been problematic. Although MS has been highlighted as a risk factor for ischemic heart disease and arteriosclerotic diseases, it was also recently shown to be associated with digestive system disorders, including upper gastrointestinal diseases. Unlike high body weight and high body mass index, abdominal obesity with visceral fat accumulation is implicated in the onset of various digestive system diseases because excessive visceral fat accumulation may cause an increase in intra-abdominal pressure, inducing the release of various bioactive substances, known as adipocytokines, including tumor necrosis factor-α, interleukin-6, resistin, leptin, and adiponectin. This review article focuses on upper gastrointestinal disorders and their association with MS, including obesity, visceral fat accumulation, and the major upper gastrointestinal diseases.

Entities:  

Keywords:  Metabolic syndrome; Obesity; Upper gastrointestinal diseases; Visceral fat accumulation

Mesh:

Year:  2016        PMID: 27372302     DOI: 10.1007/s12328-016-0668-1

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  143 in total

1.  Height, weight, and body mass index associations with gastric cancer subsites.

Authors:  M Constanza Camargo; Neal D Freedman; Albert R Hollenbeck; Christian C Abnet; Charles S Rabkin
Journal:  Gastric Cancer       Date:  2013-10-31       Impact factor: 7.370

2.  Prevalence of upper digestive endoscopy and gastric histopathology findings in morbidly obese patients.

Authors:  Judite Dietz; Jane Maria Ulbrich-Kulcynski; Katia Elisabete Pires Souto; Nelson Guardiola Meinhardt
Journal:  Arq Gastroenterol       Date:  2012 Jan-Mar

3.  The association of body mass index with Barrett's oesophagus.

Authors:  D J Stein; H B El-Serag; J Kuczynski; J R Kramer; R E Sampliner
Journal:  Aliment Pharmacol Ther       Date:  2005-11-15       Impact factor: 8.171

4.  Association between body mass and adenocarcinoma of the esophagus and gastric cardia.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Ann Intern Med       Date:  1999-06-01       Impact factor: 25.391

5.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

6.  Correlation of oesophageal acid exposure with Barrett's oesophagus length.

Authors:  R Fass; R W Hell; H S Garewal; P Martinez; G Pulliam; C Wendel; R E Sampliner
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

7.  Visceral fat adipokine secretion is associated with systemic inflammation in obese humans.

Authors:  Luigi Fontana; J Christopher Eagon; Maria E Trujillo; Philipp E Scherer; Samuel Klein
Journal:  Diabetes       Date:  2007-02-07       Impact factor: 9.461

8.  Generation and gender differences in the components contributing to the diagnosis of the metabolic syndrome according to the Japanese criteria.

Authors:  Junji Kobayashi; Kouji Nishimura; Munetoshi Matoba; Nobumasa Maekawa; Hiroshi Mabuchi
Journal:  Circ J       Date:  2007-11       Impact factor: 2.993

9.  Abdominal obesity and body mass index as risk factors for Barrett's esophagus.

Authors:  Douglas A Corley; Ai Kubo; Theodore R Levin; Gladys Block; Laurel Habel; Wei Zhao; Pat Leighton; Charles Quesenberry; Greg J Rumore; Patricia A Buffler
Journal:  Gastroenterology       Date:  2007-04-25       Impact factor: 22.682

10.  Clinical significance of hiatal hernia.

Authors:  Jong Jin Hyun; Young-Tae Bak
Journal:  Gut Liver       Date:  2011-08-18       Impact factor: 4.519

View more
  5 in total

1.  A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients.

Authors:  Nobuyuki Sugisaki; Ryuichi Iwakiri; Nanae Tsuruoka; Yasuhisa Sakata; Ryo Shimoda; Shun Fujimoto; Yuichiro Eguchi; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2018-06-12       Impact factor: 7.527

2.  The prognostic significance of metabolic syndrome and weight loss in esophageal squamous cell carcinoma.

Authors:  Bowen Liu; Bo Cheng; Cong Wang; Pengxiang Chen; Yufeng Cheng
Journal:  Sci Rep       Date:  2018-07-04       Impact factor: 4.379

3.  Sarcopenia is Independently Associated with an Increased Risk of Peptic Ulcer Disease: A Nationwide Population-Based Study.

Authors:  Youn I Choi; Jun-Won Chung; Dong Kyun Park; Kwang Pil Ko; Kyung Oh Kim; Kwang An Kwon; Jung Ho Kim; Yoon Jae Kim
Journal:  Medicina (Kaunas)       Date:  2020-03-11       Impact factor: 2.430

4.  Obesity-associated up-regulation of lipocalin 2 protects gastric mucosa cells from apoptotic cell death by reducing endoplasmic reticulum stress.

Authors:  Xin Wen; Bin Su; Mingming Gao; Jiaqi Chen; Donglei Zhou; Hui You; Nannan Li; Shuaikang Chang; Xiaoyun Cheng; Chunhua Qian; Jingyang Gao; Peng Yang; Shen Qu; Le Bu
Journal:  Cell Death Dis       Date:  2021-02-26       Impact factor: 8.469

5.  Ultrasonographic Evaluation of Fatty Pancreas in Serbian Patients with Non Alcoholic Fatty Liver Disease-A Cross Sectional Study.

Authors:  Tamara Milovanovic; Sanja Dragasevic; Milica Stojkovic Lalosevic; Sanja Zgradic; Biljana Milicic; Igor Dumic; Stefan Kmezic; Dusan Saponjski; Andrija Antic; Velimir Markovic; Dragan Popovic
Journal:  Medicina (Kaunas)       Date:  2019-10-17       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.